Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Long-Term Debt Repayments (2018 - 2025)

BeOne Medicines (BEIGF) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $14.6 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments rose 39.89% to $14.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.7 million through Dec 2025, up 27.29% year-over-year, with the annual reading at $35.7 million for FY2025, 27.29% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $14.6 million at BeOne Medicines, up from $4.3 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $14.6 million in Q4 2025, with the low at $1.5 million in Q1 2023.
  • Average Long-Term Debt Repayments over 3 years is $6.8 million, with a median of $4.7 million recorded in 2023.
  • Peak annual rise in Long-Term Debt Repayments hit 314.65% in 2024, while the deepest fall reached 57.92% in 2024.
  • Over 3 years, Long-Term Debt Repayments stood at $5.2 million in 2023, then surged by 99.89% to $10.4 million in 2024, then surged by 39.89% to $14.6 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $14.6 million, $4.3 million, and $12.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.